SCHEMBL4244085

SCHEMBL4244085

N#Cc1cccc(-c2ccc(C(=O)Nc3nc4c(C(=O)O)cccc4[nH]3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.53
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
DHODH Q02127 6/20 0.49
MAOB P27338 4/20 0.49
ADORA2A P29274 3/20 0.49
ADORA2B P29275 1/20 0.49
ADORA1 P30542 1/20 0.49
ABL1 P00519 1/20 0.48
XDH P47989 1/20 0.47
SLC22A12 Q96S37 1/20 0.47
PRSS12 P56730 1/20 0.47
PARP1 P09874 3/20 0.45
HTT P42858 1/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAOA P21397 1/20 0.43
PIN1 Q13526 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4239705 0.93 IRAK4 (0.60) IRAK4NPC1RAB9ADHODHMAOB
SCHEMBL4235830 0.92 NPC1 (0.61) IRAK4NPC1RAB9ADHODHMAOB
SCHEMBL4247108 0.90 MAOB (0.54) IRAK4NPC1RAB9ADHODHMAOB
SCHEMBL4242710 0.88 IRAK4 (0.68) IRAK4NPC1RAB9AMAOBADORA2A
SCHEMBL4239792 0.88 NPC1 (0.65) IRAK4NPC1RAB9ADHODHMAOB
SCHEMBL4243664 0.88 DHODH (0.62) NPC1RAB9ADHODHMAOBADORA2A
SCHEMBL4235663 0.88 HDAC2 (0.52) IRAK4NPC1RAB9ADHODHMAOB
SCHEMBL1202142 0.86 IRAK4 (0.50) IRAK4NPC1RAB9AMAOBADORA2A
SCHEMBL4246153 0.85 IRAK4 (0.54) IRAK4NPC1RAB9ADHODHMAOB
SCHEMBL4235195 0.84 IRAK4 (0.47) IRAK4NPC1RAB9ADHODHMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
EP-1863771-B1 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS LLC (US) 2012-11-07 EP disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP IRAK4 4792/4885NPC1 188/4885RAB9A 2719/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP IRAK4 4792/4885NPC1 188/4885RAB9A 2719/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP IRAK4 4792/4885NPC1 188/4885RAB9A 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.